The development of MIF vaccine and its therapeutic effect on murine arthritis model
MIF疫苗的研制及其对小鼠关节炎模型的治疗作用
基本信息
- 批准号:15591560
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1)We demonstrated that macrophage migration inhibitory factor (MIF) up-regulates IL-8 and IL-1β mRNA expression in synovial fibroblasts of rheumatoid arthritis (RA) patients, and that this induction is mediated by tyrosine kinase, PKC, and transcription factors Ap-1 and NF-κB. (Arthritis Rheum 2004)。2)We investigated the involvement of MIF in murine collagen-antibody induced arthritis (CAIA) model. In wild-type (wt) mice, the mRNA expression of MIF, MMP-13, and MIP-2 were enhanced in association with the onset of CAIA. In wt-mice pretreated with polyclonal anti-MIF antibody and in MIF-/-mice, the histopathological scores at the peak of arthritis were significantly reduced (p<0.05, v.s. wt-mice pretreated with nonimmune IgG). In association with this, the mRNA expression of MMP-13 and MIP-2 and infiltration of inflammatory cells in ankle joints were suppressed in the two groups. (Cytokine 2004)。3)A novel therapeutic approach for RA targeting MIF ; We attempted MIF-DNA vaccination methods. Murine MIF cDNA, modified in part by introducing T_H epitopes that encodes tetanus toxin, ovalbumin, and hen egg white-lysozyme, was cloned into pcDNA3 and prepared as MIF-DNA vaccine. After delivery of them to 8w-Balb/c mice by electroporation, CAIA was introduced. In mice pretreated with MIF-DNA vaccine, the histopathological scores at the peak of arthritis were significantly reduced (p<0.05, v.s. mice pretreated with control vector). Although under way of development, this method is promising as a novel therapeutic approach for RA (in preparation).
1)我们证明,巨噬细胞迁移抑制因子(MIF)上调类风湿关节炎(RA)患者滑膜成纤维细胞中IL-8和IL-1β mRNA的表达,并且这种诱导是由酪氨酸激酶、PKC以及转录因子Ap-1和NF-κB介导的。 (Arthritis Rheum 2004)。2)我们研究了MIF在小鼠胶原抗体诱导的关节炎(CAIA)模型中的作用。在野生型 (wt) 小鼠中,MIF、MMP-13 和 MIP-2 的 mRNA 表达随着 CAIA 的发作而增强。在用多克隆抗MIF抗体预处理的野生型小鼠和MIF-/-小鼠中,关节炎高峰期的组织病理学评分显着降低(与用非免疫IgG预处理的野生型小鼠相比,p<0.05)。与此相关,两组中 MMP-13 和 MIP-2 的 mRNA 表达以及踝关节炎症细胞的浸润均受到抑制。 (Cytokine 2004)。3)针对MIF的RA新治疗方法;我们尝试了 MIF-DNA 疫苗接种方法。通过引入编码破伤风毒素、卵清蛋白和鸡蛋清溶菌酶的T_H表位对鼠MIF cDNA进行部分修饰,将其克隆到pcDNA3中并制备成MIF-DNA疫苗。通过电穿孔将它们递送至 8w-Balb/c 小鼠后,引入 CAIA。在用 MIF-DNA 疫苗预处理的小鼠中,关节炎高峰期的组织病理学评分显着降低(与用对照载体预处理的小鼠相比,p<0.05)。尽管正在开发中,但该方法有望成为 RA 的一种新型治疗方法(正在准备中)。
项目成果
期刊论文数量(36)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transtrochanteric rotational osteotomy for osteonecrosis of femoral head : Relationship between radiographic features and secondary collapse.
经转子旋转截骨术治疗股骨头坏死:放射学特征与继发性塌陷之间的关系。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Onodera S;Majima T;Abe Y;Ito H;Matsuno T;Minami A
- 通讯作者:Minami A
Macrophage migration inhibitory factor (MIF) up-regulates expression of interleukin (IL)-8 mRNA in synovial fibroblasts of rheumatoid arthritis. Common transcriptional regulatory mechanism between IL-8 and IL-1β.
巨噬细胞迁移抑制因子 (MIF) 上调类风湿性关节炎滑膜成纤维细胞中白细胞介素 (IL)-8 mRNA 的表达 IL-8 和 IL-1β 之间的共同转录调节机制。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Onodera;S.
- 通讯作者:S.
Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF)
- DOI:10.1016/j.cyto.2004.02.007
- 发表时间:2004-06-07
- 期刊:
- 影响因子:3.8
- 作者:Ichiyama, H;Onodera, S;Tohyama, H
- 通讯作者:Tohyama, H
Transtrochanteric rotational osteotomy for osteonecrosis of femoral head ; Relationship between radiographic features and secondary collapse.
经转子旋转截骨术治疗股骨头坏死;
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Ichiyama H;Onodera S;Nishihira J;Ishibashi T;Nakayama T;Minami A;Yasuda K;Tohyama H;Shin Onodera;Shin Onodera;Hiroki Ichiyama;Shin Onodera
- 通讯作者:Shin Onodera
Up-regulation of macrophage migration-inhibitory factor expression after compression-induced spinal cord injury in rats
- DOI:10.1007/s00401-004-0853-z
- 发表时间:2004-07-01
- 期刊:
- 影响因子:12.7
- 作者:Koda, M;Nishio, Y;Yamazaki, M
- 通讯作者:Yamazaki, M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ONODERA Shin其他文献
ONODERA Shin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ONODERA Shin', 18)}}的其他基金
Role of MIF on the process of fracture healing and the effect of its regulation
MIF对骨折愈合过程的作用及其调节作用
- 批准号:
21591909 - 财政年份:2009
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of MIF in wear particle-induced oeteolysis and its regulation by MIF-DNA vaccination
MIF 在磨损颗粒诱导的溶胶中的作用及其通过 MIF-DNA 疫苗接种的调节
- 批准号:
19591746 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The pathomechanism of postmenopausal osteoporosis-the involvement of MIF and therapeutic approach using MIF-DNA vaccine
绝经后骨质疏松症的发病机制——MIF的参与及MIF-DNA疫苗的治疗方法
- 批准号:
17591542 - 财政年份:2005
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Targeting DKK1 with a DNA Vaccine to Prevent Development of Multiple Myeloma
用 DNA 疫苗靶向 DKK1 预防多发性骨髓瘤的发展
- 批准号:
10874135 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
临床就绪的 MACH-1 基因枪,用于提供通用流感 DNA 疫苗
- 批准号:
10761364 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
A Single-dose DNA vaccine platform to safely induce protective immunity against Zika
单剂量 DNA 疫苗平台可安全诱导针对寨卡病毒的保护性免疫力
- 批准号:
10026208 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Small Business Research Initiative
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
- 批准号:
10340654 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
- 批准号:
10571883 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
整合素激活剂佐剂 DNA 疫苗对抗克氏锥虫感染
- 批准号:
10665082 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
整合素激活剂佐剂 DNA 疫苗对抗克氏锥虫感染
- 批准号:
10544403 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Development of an intradermal or inhaled DNA vaccine for COVID-19 and beyond
开发针对 COVID-19 及其他疾病的皮内或吸入 DNA 疫苗
- 批准号:
2599978 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies
一种新型 DNA 疫苗,通过刺激高亲和力 CD8 T 细胞和强中和抗体来提供持久的免疫力
- 批准号:
73437 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Collaborative R&D
Vaccination with self-launching RhCMV/SIV DNA vaccine vectors
使用自启动 RhCMV/SIV DNA 疫苗载体进行疫苗接种
- 批准号:
10037603 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别: